Citi Is Buyer on Weakness in Alexion Pharmaceuticals (ALXN), Sees Fair Value around $131-$133

Stifel Reiterates Hold Rating on Alexion Pharmaceuticals (ALXN)

Stifel analyst Paul Matteis reiterated a Hold rating and {REMOVEPT} price target on Alexion Pharmaceuticals (NASDAQ: ALXN)

The analyst comments "While the implications of a theoretical Soliris biosimilar launch (assuming ALXN converts) remain debatable, we expect the IPR institution decision this morning... More

Alexion (ALXN) Soliris IPR Surprising, But Long-Term Impact 'Limited' - Raymond James

Raymond James analyst Steven Seedhouse weighed in on Alexion Pharmaceuticals (NASDAQ: ALXN) after the PTAB decided to institute an inter partes review (IPR) of eculizumab's U.S. composition of matter, method of use, and formulation patents, which currently expire in ~2027..

Seedhouse said while the news was uprising the long-term impact should be... More

Piper Jaffray Defends Alexion Pharmaceuticals (ALXN)

Piper Jaffray analyst Chris Raymond reiterated an Overweight rating and $180.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN).

The analyst sees an opportunity to buy the dip on Friday's selloff as the valuation is now more attractive.

For an analyst ratings summary and... More

Alexion Pharmaceuticals (ALXN) PTAB News an 'Incremental Negative' - Baird

Baird analyst Michael Ulz weighed in on Alexion Pharmaceuticals (NASDAQ: ALXN) after the PTAB announced a decision to institute all three IPRs filed by Amgen against key Soliris patents (149, 880 and 504) expiring in 2027.

"While we will have to wait 12 months for a final... More

Increasing unusual option volume: ALXN COO ULTA DELL AMBA

Increasing unusual option volume: ALXN COO ULTA DELL AMBA

Pre-Open 08/30: (SEAC) (AMBA) (MSGN) Higher (ULTA) (AOBC) (ALXN) Lower (more...)

Pre-Open Movers

SeaChange Int'l (NASDAQ: SEAC) 26.9% HIGHER; reported Q2 EPS of $0.00, $0.07 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $18.8 million versus the consensus estimate of $14.66 million. SeaChange is also announcing that effective immediately, Yossi Aloni, has been appointed President and Chief Executive Officer of the Company.

Ulta Salon (NASDAQ: ULTA) 24.6% LOWER; reported Q2 EPS of $2.76, $0.04 worse than the analyst estimate of $2.80. Revenue for the quarter came in at $1.67 billion versus the consensus estimate of $1.68... More

Alexion Pharma (ALXN) Soliris patents get review on Amgen (AMGN) challenge at patent office - Bloomberg

Alexion Pharma (NASDAQ: ALXN) Soliris patents get review on Amgen (NASDAQ: AMGN) challenge at patent office - Bloomberg